Welcome!

News Feed Item

Biogen Idec's Tecfidera Captures the Largest U.S. Neurologist-Reported Patient Share Among Oral Disease-Modifying Multiple Sclerosis Therapies Ten Months Post-Launch

Both First-Line and Switch Starts are Driving Early Uptake of Teva's Copaxone 40 mg Three-Times-Weekly, According to Findings from Decision Resources Group

BURLINGTON, Mass., March 19, 2014 /PRNewswire/ -- Decision Resources Group finds that Biogen Idec's Tecfidera, the third-to-market oral disease-modifying therapy (DMT), has become the patient share leader among the oral options available for the treatment of relapsing forms of multiple sclerosis (MS) ten months post-launch, according to surveyed U.S. neurologists. Tecfidera currently captures 10 percent of weighted U.S. patient share compared to 7 percent for Novartis's Gilenya and 3 percent for Sanofi/Genzyme's Aubagio. With the oral DMT class uptake, platform injectable DMT shares continue to decrease with neurologists reporting a significant decline in Bayer HealthCare's Betaseron share compared to a year ago. Regardless of the market changes, Teva's Copaxone and Biogen Idec's Avonex maintain their position as the patient share market leaders.

Decision Resources Group Logo

Other key findings from the TreatmentTrends: Multiple Sclerosis Q1 2014 (US) report:

  • Copaxone: Copaxone 40 mg three-times-weekly (3TW), which was approved and launched just prior to the fielding of this survey, captures 6 percent of both recent first-line and switch starts among relapsing-remitting MS (RR-MS) patients. With no increase in patient share of the brand franchise compared to previous waves, early prescribing of the new formulation appears to be primarily coming from Copaxone 20 mg switches.
  • Tecfidera, Gilenya and Tysabri: Suggesting a shift in neurologists' perceptions of the RR-MS treatment paradigm over the past six months, significantly more neurologists now report Tecfidera as their preferred second-line DMT and Gilenya or Biogen Idec's Tysabri as their preferred third-line option for RR-MS patients.
  • Emerging monoclonal antibodies: Surveyed U.S. neurologists estimate a higher potential peak patient share for the emerging monoclonal antibodies among primary–progressive MS (PP-MS) patients compared to RR-MS patients. This separation is most apparent for Roche/Genentech's ocrelizumab possibly due to the product's ongoing clinical development programs for PP-MS—an indication that 81 percent of neurologists agree they would find highly desirable in a new DMT.

Comments from Decision Resources Group Senior Director Virginia Schobel, M.Sc.:

  • "In line with Teva's aim to switch 45 percent of Copaxone-treated patients to the new formulation within the next few months, surveyed neurologists estimate that 48 percent of patients currently prescribed Copaxone 20 mg will be switched to Copaxone 40 mg 3TW by the end of the year. The remaining patients are anticipated to either stay on the 20 mg formulation, switch to generic glatiramer acetate (if launched in June), or switch to another branded DMT."
  • "Reflecting the changing dynamics in the MS market, significantly more neurologists report being most likely to initiate Avonex and Betaseron when managed care requires step therapy compared to a year ago, suggesting that cost controls may be driving some of these agents' continued use."

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
[email protected]

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO

SOURCE Decision Resources Group

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Gemini is Yahoo’s native and search advertising platform. To ensure the quality of a complex distributed system that spans multiple products and components and across various desktop websites and mobile app and web experiences – both Yahoo owned and operated and third-party syndication (supply), with complex interaction with more than a billion users and numerous advertisers globally (demand) – it becomes imperative to automate a set of end-to-end tests 24x7 to detect bugs and regression. In th...
"With Digital Experience Monitoring what used to be a simple visit to a web page has exploded into app on phones, data from social media feeds, competitive benchmarking - these are all components that are only available because of some type of digital asset," explained Leo Vasiliou, Director of Web Performance Engineering at Catchpoint Systems, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"Venafi has a platform that allows you to manage, centralize and automate the complete life cycle of keys and certificates within the organization," explained Gina Osmond, Sr. Field Marketing Manager at Venafi, in this SYS-CON.tv interview at DevOps at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Michael Maximilien, better known as max or Dr. Max, is a computer scientist with IBM. At IBM Research Triangle Park, he was a principal engineer for the worldwide industry point-of-sale standard: JavaPOS. At IBM Research, some highlights include pioneering research on semantic Web services, mashups, and cloud computing, and platform-as-a-service. He joined the IBM Cloud Labs in 2014 and works closely with Pivotal Inc., to help make the Cloud Found the best PaaS.
Creating replica copies to tolerate a certain number of failures is easy, but very expensive at cloud-scale. Conventional RAID has lower overhead, but it is limited in the number of failures it can tolerate. And the management is like herding cats (overseeing capacity, rebuilds, migrations, and degraded performance). In his general session at 18th Cloud Expo, Scott Cleland, Senior Director of Product Marketing for the HGST Cloud Infrastructure Business Unit, discussed how a new approach is neces...
"This week we're really focusing on scalability, asset preservation and how do you back up to the cloud and in the cloud with object storage, which is really a new way of attacking dealing with your file, your blocked data, where you put it and how you access it," stated Jeff Greenwald, Senior Director of Market Development at HGST, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Cloud-enabled transformation has evolved from cost saving measure to business innovation strategy -- one that combines the cloud with cognitive capabilities to drive market disruption. Learn how you can achieve the insight and agility you need to gain a competitive advantage. Industry-acclaimed CTO and cloud expert, Shankar Kalyana presents. Only the most exceptional IBMers are appointed with the rare distinction of IBM Fellow, the highest technical honor in the company. Shankar has also receive...
"Evatronix provides design services to companies that need to integrate the IoT technology in their products but they don't necessarily have the expertise, knowledge and design team to do so," explained Adam Morawiec, VP of Business Development at Evatronix, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Business professionals no longer wonder if they'll migrate to the cloud; it's now a matter of when. The cloud environment has proved to be a major force in transitioning to an agile business model that enables quick decisions and fast implementation that solidify customer relationships. And when the cloud is combined with the power of cognitive computing, it drives innovation and transformation that achieves astounding competitive advantage.
"We work around really protecting the confidentiality of information, and by doing so we've developed implementations of encryption through a patented process that is known as superencipherment," explained Richard Blech, CEO of Secure Channels Inc., in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"I focus on what we are calling CAST Highlight, which is our SaaS application portfolio analysis tool. It is an extremely lightweight tool that can integrate with pretty much any build process right now," explained Andrew Siegmund, Application Migration Specialist for CAST, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
The Founder of NostaLab and a member of the Google Health Advisory Board, John is a unique combination of strategic thinker, marketer and entrepreneur. His career was built on the "science of advertising" combining strategy, creativity and marketing for industry-leading results. Combined with his ability to communicate complicated scientific concepts in a way that consumers and scientists alike can appreciate, John is a sought-after speaker for conferences on the forefront of healthcare science,...
"Software-defined storage is a big problem in this industry because so many people have different definitions as they see fit to use it," stated Peter McCallum, VP of Datacenter Solutions at FalconStor Software, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
"Our strategy is to focus on the hyperscale providers - AWS, Azure, and Google. Over the last year we saw that a lot of developers need to learn how to do their job in the cloud and we see this DevOps movement that we are catering to with our content," stated Alessandro Fasan, Head of Global Sales at Cloud Academy, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at Cloud Expo, Ed Featherston, a director and senior enterprise architect at Collaborative Consulting, discussed the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.